Evan David Seigerman
Stock Analyst at BMO Capital
(2.45)
# 2,314
Out of 4,835 analysts
38
Total ratings
26.47%
Success rate
0.34%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan David Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARVN Arvinas | Maintains: Outperform | $20 → $10 | $6.49 | +54.08% | 1 | May 5, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $865 → $800 | $594.32 | +34.61% | 6 | Apr 30, 2025 | |
| NVO Novo Nordisk | Downgrades: Market Perform | $105 → $64 | $64.37 | -0.57% | 6 | Apr 17, 2025 | |
| MRK Merck & Co. | Maintains: Market Perform | $105 → $96 | $76.06 | +26.22% | 4 | Feb 5, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $208 → $215 | $184.02 | +16.84% | 7 | Feb 3, 2025 | |
| REPL Replimune Group | Maintains: Outperform | $18 → $27 | $7.85 | +243.95% | 3 | Jan 22, 2025 | |
| GPCR Structure Therapeutics | Maintains: Outperform | $83 → $100 | $25.17 | +297.30% | 2 | Jun 7, 2024 | |
| AMGN Amgen | Maintains: Outperform | $336 → $355 | $272.41 | +30.32% | 3 | May 3, 2024 | |
| PFE Pfizer | Reiterates: Outperform | $33 → $36 | $22.83 | +57.69% | 4 | May 2, 2024 | |
| CADL Candel Therapeutics | Maintains: Outperform | $9 → $3 | $5.35 | -43.93% | 1 | May 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $369 → $396 | $757.39 | -47.72% | 1 | Sep 6, 2022 |
Arvinas
May 5, 2025
Maintains: Outperform
Price Target: $20 → $10
Current: $6.49
Upside: +54.08%
Regeneron Pharmaceuticals
Apr 30, 2025
Maintains: Outperform
Price Target: $865 → $800
Current: $594.32
Upside: +34.61%
Novo Nordisk
Apr 17, 2025
Downgrades: Market Perform
Price Target: $105 → $64
Current: $64.37
Upside: -0.57%
Merck & Co.
Feb 5, 2025
Maintains: Market Perform
Price Target: $105 → $96
Current: $76.06
Upside: +26.22%
AbbVie
Feb 3, 2025
Maintains: Outperform
Price Target: $208 → $215
Current: $184.02
Upside: +16.84%
Replimune Group
Jan 22, 2025
Maintains: Outperform
Price Target: $18 → $27
Current: $7.85
Upside: +243.95%
Structure Therapeutics
Jun 7, 2024
Maintains: Outperform
Price Target: $83 → $100
Current: $25.17
Upside: +297.30%
Amgen
May 3, 2024
Maintains: Outperform
Price Target: $336 → $355
Current: $272.41
Upside: +30.32%
Pfizer
May 2, 2024
Reiterates: Outperform
Price Target: $33 → $36
Current: $22.83
Upside: +57.69%
Candel Therapeutics
May 15, 2023
Maintains: Outperform
Price Target: $9 → $3
Current: $5.35
Upside: -43.93%
Sep 6, 2022
Maintains: Outperform
Price Target: $369 → $396
Current: $757.39
Upside: -47.72%